← All trials
NCT04348045
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- Apr 15, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 307
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)Lead sponsor
- AstraZenecaCollaborator
- Assistance Publique - Hôpitaux de ParisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.